Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

781

Shown on this page

Current sort

Live official records

Conditions: Obesity
Interventions: Social Network Intervention, Individual Lifestyle Intervention, Social Network Member; Behavioral · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions: Single arterial graft, Multiple arterial grafting; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 42
States / cities: Los Angeles, California • Pomona, California • San Francisco, California + 36 more

Conditions: Endometrial Cancer
Interventions: Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more

Conditions: Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
Interventions: INCB057643, Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 14 more

Conditions: NonSegmental Vitiligo
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • Montgomery, Alabama • Fountain Valley, California + 25 more

Conditions: Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions: TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 28 Years to 52 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Surgical Wound, Post Operative Wound Infection
Interventions: Time to bathing (delayed), Time to bathing (early); Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Pembrolizumab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 3
States / cities: New York, New York

Conditions: Unruptured Wide-neck Aneurysms
Interventions: Citadel Embolization Device; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Walnut Creek, California + 18 more

Conditions: Depression, Suicidal Ideation, Major Depressive Disorder, Depressive Disorder
Interventions: "Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Limb-Threatening Ischemia
Interventions: Esprit BTK System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Fresno, California + 27 more

Conditions: Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel; Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 883
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more

About this Weill Cornell Medicine institution page

What this page lists: ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Weill Cornell Medicine

Filter and sort this campus

Live official records

Reducing Obesity Using Social Ties Program

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Early Versus Delayed Bathing of Orthopaedic Surgical Wounds

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Citadel Embolization Device Study

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

Esprit BTK Post-Approval Study

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

About this Weill Cornell Medicine institution page